{"entity":{"id":"rezvilutamide","kind":"drug","name":"Rezvilutamide","aka":[],"tldr":"Rezvilutamide is Hengrui's androgen receptor blocker, approved in China in 2022 for high-volume metastatic hormone-sensitive prostate cancer on the CHART trial, where it improved survival over bicalutamide.","summary":"Jiangsu Hengrui's rezvilutamide (SHR3680) received NMPA approval in June 2022 for high-volume metastatic hormone-sensitive prostate cancer with androgen deprivation, after the CHART phase 3 trial showed longer radiographic progression-free and overall survival than bicalutamide. Further phase 3 trials in non-metastatic and castration-resistant disease are registered. It is not approved outside China.","status":"approved","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Rezvilutamide","url":"https://clinicaltrials.gov/search?intr=SHR3680"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["endocrine-therapy"],"targets":["androgen-receptor"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07241416"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, curated)","editedOn":"2026-09-16"},"code":"SHR3680","modality":"Oral androgen receptor antagonist","mechanism":"A second-generation antagonist of the androgen receptor, the class of enzalutamide, apalutamide and darolutamide, blocking androgen signalling in prostate cancer cells.","approvals":[{"region":"CN","year":2022,"indication":"High-volume metastatic hormone-sensitive prostate cancer with androgen deprivation therapy"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/rezvilutamide/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"}],"target":[{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/"}],"trial":[{"id":"nct07407283","kind":"trial","name":"A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer","route":"/trials/nct07407283/"},{"id":"nct07241416","kind":"trial","name":"A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer","route":"/trials/nct07241416/"},{"id":"nct07230106","kind":"trial","name":"A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer","route":"/trials/nct07230106/"}]}}